Skip to main content

Table 3 Correlation between clinicopathological variables and radiologic response rate

From: Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer

Variables   No. of Pts Responders (RR %) p-value*
Age < 50
≥ 50
102
43
69 (67.6)
31 (72.1)
0.597
Performance ECOG 0–1
ECOG 2
139
6
95 (68.3)
5 (83.3)
0.666
Initial clinical stage IIA, IIB, IIIA
IIIB, IIIC
93
52
64 (68.8)
36 (69.2)
0.959
pCR No 134 89 (66.4) 0.018
  Yes 11 11 (100.0)  
Nuclear grade I, II 41 22 (53.7) 0.069
  III 87 61 (70.1)  
  Unknown 17 -  
Histologic grade I, II 39 24 (61.5) 0.741
  III 82 53 (64.6)  
  Unknown 24 -  
ER Positive 64 41 (64.1) 0.257
  Negative 81 59 (72.8)  
PR Positive 44 28 (63.6) 0.360
  Negative 101 72 (71.3)  
bcl-2 Positive 63 45 (71.4) 0.749
  Negative 74 51 (68.9)  
  Unknown 8 -  
Ki-67 Low expression# 56 34 (60.7) 0.066
  High expression 85 64 (75.3)  
  Unknown 4 -  
p53 Low expression# 67 43 (64.2) 0.219
  High expression 76 56 (73.7)  
  Unknown 2 -  
c-erbB2 0/+/++ 107 76 (71.0) 0.368
  +++ 38 24 (63.2)  
Triple negative No 98 61 (62.2) 0.012
  Yes 47 39 (83.0)  
  1. RR, response rate; pCR, pathologic complete response; ER, estrogen receptor; PR, progesterone receptor.
  2. *based on Pearson's χ2 test (using Fisher's exact test if N ≤ 5).
  3. #Ki-67 with ≤ 5% and p53 with <25% were considered as low expression.